DBVT · DBV Technologies S.A.

On April 30, 2026, the Board of Directors of DBV Technologies S.A. approved the 2026 Performance Share Unit Plan, authorizing a significant equity grant to CEO Daniel Tassé. The grant consists of 1,740,000 Performance Share Units, with an award grant date of May 5, 2026. This compensation package is explicitly designed to align the CEO's incentives with critical regulatory milestones for the Company's lead product candidate, Viaskin Peanut.

The structure of the award is heavily performance-based. Vesting is contingent upon the U.S. Food and Drug Administration (FDA) accepting for review the Biologics License Applications (BLAs) for Viaskin Peanut in two distinct patient populations. Specifically, 870,000 PSUs (50% of the total award) are linked to FDA acceptance for the 4-7 age group, and the remaining 870,000 PSUs are linked to acceptance for the 1-3 age group. The Plan includes a provision that if a single BLA covering both age groups is accepted, the performance condition is deemed fully satisfied.

The vesting schedule imposes a strict deadline of July 1, 2028, for the achievement of these regulatory milestones; failure to meet the conditions by this date results in automatic cancellation and forfeiture of the PSUs. Furthermore, the award is subject to a Continued Employment Condition, requiring Mr. Tassé to remain as CEO through the Vesting Date. The delivery of vested shares is structured to occur in four equal installments spanning from July 2028 to January 2030, promoting long-term retention. In the event of a Change in Control, all performance conditions are deemed achieved, although the continued employment requirement remains in effect. This grant underscores the Board's focus on securing regulatory approval for Viaskin Peanut as the primary value driver for shareholders.